Tratamiento con medicamentos para la esclerosis múltiple en Israel — reciba 3 opciones de clínicas personalizadas

Multiple sclerosis treatment in Israel centers on high-efficacy disease-modifying therapies (DMTs) like Ocrevus, Copaxone, and Tysabri. Specialists at JCI-accredited centers like Sheba and Hadassah utilize oral, injectable, and infusion protocols to reduce relapse rates. Advanced neuro-regenerative options, including stem cell therapy, are also available.

• Available infusions: Ocrevus (ocrelizumab), Tysabri (natalizumab), and Lemtrada (alemtuzumab) treat highly active cases.
• Oral therapies: Clinics prescribe Gilenya, Tecfidera, and Mavenclad for long-term immunological maintenance.
• Local innovation: Copaxone (glatiramer acetate), developed in Israel, remains a primary injectable option.
• Advanced procedures: Specialists utilize stem cell therapy and plasmapheresis for treatment-resistant neurological damage.

Bookimed Expert Insight: Israeli neurology centers prioritize early, high-efficacy intervention using B-cell depletion therapies like Ocrevus. Data shows centers like Hadassah and Sourasky lead in neuro-regenerative research. This allows patients to access experimental stem cell protocols when standard DMTs fail to halt progression.

Patient Consensus: Patients often highlight the local significance of Copaxone and the availability of Ocrevus for progressive forms. Many note that standard IV steroid sessions effectively manage acute relapses during their stay.

Disease-modifying therapies (DMTs) effectively reduce MS relapses by 29% to over 60% and significantly slow disability accumulation by limiting new brain lesions. Patients can expect long-term disease stabilization, though these treatments primarily prevent new damage rather than repairing existing neurological deficits or scars.

• Relapse reduction: High-efficacy infusions like Ocrevus reduce relapse rates by over 60% annually.
• Disability progression: Early intervention with DMTs is proven to delay permanent neurodegeneration and loss.
• MRI outcomes: Consistent therapy stops the formation of active inflammatory lesions on brain scans.
• Aggressive options: Specialized centers offer stem-cell transplantation (HSCT) for treatment-resistant or rapidly progressing cases.

Bookimed Expert Insight: Israeli neuroimmunology protocols prioritize ultra-fast infusions like Briumvi, which takes only 1 hour twice yearly. While standard DMTs maintain health, Hadassah Medical Center and Sheba Medical Center lead in stem-cell research. This allows patients with aggressive MS to access treatments that are often unavailable or restricted in other regions.

Patient Consensus: Patients report high stability with no new lesions for 5 years or more using Ocrevus. Most highlight that monthly injections or twice-yearly infusions provide an excellent quality of life with minimal side effects.

Multiple sclerosis medications in Israel primarily use disease-modifying therapies (DMTs) like Ocrevus (ocrelizumab) to modulate immune responses. Common side effects include flu-like symptoms from injectables, gastrointestinal distress from oral agents, and infusion-related reactions. Serious safety concerns involve increased infection risk and potential liver enzyme elevation requiring regular monitoring.

• Ocrevus safety: Infusion reactions like itching or rashes are common but manageable during administration.
• Infection monitoring: Suppressed immune systems increase susceptibility to respiratory infections and rare viral complications.
• Liver function: Medications like Aubagio and Gilenya require frequent blood tests for hepatotoxicity screening.
• Relapse prevention: Stopping medications like Gilenya suddenly may trigger severe relapse without medical supervision.

Bookimed Expert Insight: While patients often fear long side effect lists, data from Sheba and Hadassah shows high-efficacy infusions like Ocrevus often have fewer daily disruptions than oral therapies. Hospitals in Israel emphasize immunological resetting, where specialists like Dr. Dimitrios Karussis prioritize long-term safety by monitoring specific white blood cell subsets rather than just general counts.

Patient Consensus: Most patients report that initial side effects are temporary and manageable through simple lifestyle adjustments. Many agree that the risk of irreversible disability from untreated MS far outweighs the practical challenges of medication management.

Ideal candidates for disease-modifying therapy include individuals with active relapsing-remitting multiple sclerosis or clinically isolated syndrome showing inflammatory activity. Treatment should begin immediately after a confirmed diagnosis. Early intervention within the first year is vital to prevent permanent brain atrophy and long-term disability progression.

• Treatment timeframe: Start therapy immediately. Delaying until a second relapse increases risk of permanent damage.
• Clinical candidacy: Suitable for patients with new MRI lesions, recent relapses, or EDSS scores under 4.0.
• Age factor: Patients diagnosed before age 35 often respond best to early, aggressive treatment protocols.
• Modern approach: Experts now favor high-efficacy drugs like Ocrevus over traditional step-ladder therapy methods.

Bookimed Expert Insight: Israel is a global leader in neuroimmunology. Specialists like Dr. Arnon Karni at Sourasky Medical Center and Dr. Dimitrios Karussis at Hadassah utilize advanced protocols beyond standard medication. While standard Ocrevus therapy ranges from $16,500 to $22,800, top Israeli centers often integrate regenerative medicine and clinical-trial-grade immunotherapies that are unavailable in many other regions.

Patient Consensus: Patients emphasize that waiting for symptoms to worsen is a mistake. Most recommend seeing a dedicated neuroimmunologist rather than a general neurologist to access high-potency treatments early.

Diagnostic and monitoring protocols for multiple sclerosis in Israel follow strict McDonald Criteria to ensure medication safety. Before treatment, patients undergo neurological exams, baseline MRI scans of the brain and spine, and blood screenings for infections like Hepatitis B and JC virus.

• Baseline imaging: Full-spine MRI including brain, cervical, and thoracic regions establishes disease dissemination.
• Neurological evaluation: Specialists assess coordination, vision, and balance to establish a clinical baseline.
• Laboratory screenings: Complete blood counts and liver function tests ensure organ health before starting.
• Specialized tracking: Regular JC virus monitoring and B-cell counts are required for high-efficacy therapies.

Bookimed Expert Insight: Israel's neuroimmunology centers, such as Hadassah, often combine standard drug protocols with advanced stem cell research. Data shows that clinics like Sourasky use specialized Electromyography (EMG) and Electroneurography to assess nerve damage before starting medication. This helps precisely tailor the dosage of intensive therapies like Ocrevus from the first day.

Patient Consensus: Patients emphasize the necessity of bringing a full-spine MRI taken within the last 3 months. Many recommend advocating for both cervical and thoracic scans alongside brain imaging to prevent diagnostic delays.

Multiple sclerosis medication in Israel typically continues indefinitely as long-term maintenance to prevent new CNS damage. While maintenance therapies are lifelong, immune reconstitution therapies provide control after a 2-year course. Treatment changes depend on new MRI lesions, clinical relapses, intolerable side effects, or pregnancy planning.

• Therapy duration: Maintenance drugs are generally lifelong; immune reconstitution involves 2-year treatment cycles.
• Switching triggers: New lesions or relapses indicate breakthrough disease, requiring high-efficacy drug adjustments.
• Monitoring protocols: Periodic MRI scans and B-cell level monitoring guide dosage and timing.
• Pregnancy planning: Patients transition to specific pregnancy-safe options before conception to ensure safety.

Bookimed Expert Insight: Israeli centers like Hadassah Medical Center lead in specialized B-cell depletion and stem cell protocols. Our data shows centers here favor early, aggressive intervention. Doctors like Dimitrios Karussis utilize triple-board expertise to transition patients from standard maintenance to advanced immune reconstitution when conventional drugs fail.

Patient Consensus: Patients emphasize that early therapy start is vital for long-term mobility. Many find that monitoring B-cell levels helps personalize their infusion schedules.

Multiple Sclerosis specialists in Israel are board-certified neurologists with sub-specialization in neuroimmunology. These experts typically hold dual MD-PhD degrees and complete international fellowships at institutions like Harvard. Most practice at JCI-accredited academic centers like Sheba or Sourasky, focusing on advanced disease-modifying therapies and stem cell research.

• Specialized training: Experts often hold dual certifications in neurology and neuroimmunology for immune-targeted care.
• Academic leadership: Many lead researchers at Hebrew University or Tel Aviv University publish extensive MS studies.
• International fellowships: Top specialists frequently complete postdoctoral training at the Paris Pasteur Institute or Harvard.
• High-volume experience: Specialists at major centers manage complex cases within patient populations exceeding 1,000,000 annually.

Bookimed Expert Insight: Israeli MS specialists at Hadassah and Sheba stand out for their rare integration of bone marrow transplantation into MS protocols. While many global neurologists focus solely on medication, experts like Dr. Dimitrios Karussis hold specific European credentials for stem cell therapy. This dual expertise allows patients access to regenerative options not typically found in standard neurology departments.

Patient Consensus: Patients emphasize seeking specialists at university-affiliated hospitals like Sourasky or Hadassah for dedicated neuro-immunological monitoring. They often highlight the importance of regular 3–6 month MRI reviews to track treatment efficacy.